Critical Therapeutics and Dey have entered into an agreement for the co-promotion of inhalation product Perforomist, indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic
Elaprase is an enzyme replacement therapy developed by Shire Human Genetic Therapies. Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with
The report demonstrates that the drug, HE3235, significantly inhibited tumor growth in a preclinical model of hormone-independent prostate cancer utilizing human tumor cells. Mechanism of action data was
In this study, a 28-day treatment course of antibiotic aztreonam lysine for inhalation improved respiratory symptoms as assessed by the cystic fibrosis questionnaire-revised (CFQ-R), a patient-reported outcome tool.
As per FDA published guidance for patient reported outcome (PRO) studies, the pivotal efficacy studies of LibiGel require the use of validated methods to measure sexual events and
The recently issued patent will expire in 2023. Dyax now has a total of nine issued US patents covering DX-88 as well as other related kallikrein inhibitors and
Adlea is a long-acting, non-opiate analgesic drug candidate designed to provide pain relief for weeks to months after a single local application during the surgical procedure. The trial
The agreement is one of two clinical studies intended to form part of the application for marketing authorization. The randomized, double-blind placebo-controlled multi-center clinical trial will be conducted
Results from the study indicate that a statistically significantly greater proportion of subjects dosed once-a-day with 1.5 grams of granulated mesalamine remained relapse-free over six months of treatment
The primary endpoint of the eight-week study was LDL-C reduction, with secondary endpoints of HDL-C increases and effects on other lipoproteins and apolipoproteins and blood pressure evaluated across
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.